<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211065</url>
  </required_header>
  <id_info>
    <org_study_id>BT16-34083</org_study_id>
    <nct_id>NCT03211065</nct_id>
  </id_info>
  <brief_title>Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig</brief_title>
  <official_title>The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non Hodgkin's Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rochester General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rochester General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy
      (replacement of antibodies, which are infection-fighting proteins) in patients with a type of
      blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy)
      and have an abnormal immune system putting them at increased risk of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose evaluating patients with B cell non-Hodgkin's lymphoma treated with
      rituximab within the past 2 years with baseline immunoglobulin levels and vaccine responses
      to polysaccharide (pneumococcus, meningococcus) and peptide (tetanus, diphtheria) antigens.
      Patients with impaired vaccine responses may benefit most from immunoglobulin prophylaxis and
      will be proactively started on 20% subcutaneous replacement therapy. This study is novel in
      that it will stratify patients according to their humoral response to polysaccharide and
      peptide vaccines, and will proactively initiate therapy with the new 20% subcutaneous
      immunoglobulin in those with impaired humoral response rather than starting it after
      infections occur. This will potentially lead to decreased infections and improved quality of
      life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of non-neutropenic infections per subject requiring antibiotics in the year after enrollment</measure>
    <time_frame>1 year</time_frame>
    <description>How many antibiotics are prescribed in one year for any type of infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life score for participants during the one year enrollment</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed with Short Form 36 (SF 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related adverse effects as assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Secondary Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Immunoglobulin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% subcutaneous immunoglobulin</intervention_name>
    <description>Subcutaneous Immunoglobulin</description>
    <arm_group_label>Immunoglobulin therapy</arm_group_label>
    <other_name>Cuvitru</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of B cell non-Hodgkin's lymphoma

          2. Medically stable

          3. Able to understand and willingness to sign a written informed consent

          4. Able to comply with study procedures

        Exclusion Criteria:

          1. Previously diagnosed primary immunodeficiency

          2. Additional immunosuppressive states

          3. Ongoing therapy with Ig replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Shahzad Mustafa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Regional Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tia Albro, NP</last_name>
    <phone>585-922-3536</phone>
    <email>Tia.Albro@rochesterregional.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allergy and Immunology, 222 Alexander Street</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Antle, LPN, CCRC</last_name>
      <phone>585-245-2677</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):594-600. doi: 10.1016/j.jaip.2014.06.003. Epub 2014 Aug 7. Review.</citation>
    <PMID>25213054</PMID>
  </reference>
  <reference>
    <citation>Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999 Jun;17(6):1851-7.</citation>
    <PMID>10561225</PMID>
  </reference>
  <reference>
    <citation>McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.</citation>
    <PMID>9704735</PMID>
  </reference>
  <reference>
    <citation>Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005 Oct;31(6):456-73. Epub 2005 Jul 28. Review.</citation>
    <PMID>16054760</PMID>
  </reference>
  <reference>
    <citation>Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011 Jan;15(1):e2-16. doi: 10.1016/j.ijid.2010.03.025. Epub 2010 Nov 11. Review.</citation>
    <PMID>21074471</PMID>
  </reference>
  <reference>
    <citation>van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.</citation>
    <PMID>16873669</PMID>
  </reference>
  <reference>
    <citation>Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106-11. doi: 10.1016/j.clml.2012.11.011. Epub 2012 Dec 29.</citation>
    <PMID>23276889</PMID>
  </reference>
  <reference>
    <citation>Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006 Sep;17(9):1424-7.</citation>
    <PMID>16966368</PMID>
  </reference>
  <reference>
    <citation>Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One. 2014 Jun 27;9(6):e100324. doi: 10.1371/journal.pone.0100324. eCollection 2014.</citation>
    <PMID>24971644</PMID>
  </reference>
  <reference>
    <citation>Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, Longhurst HJ, Grigoriadou S, Buckland M, Kanfer E, Hanson S, Ibrahim MA, Grimbacher B, Chee R, Seneviratne SL. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014 Oct;107(10):821-8. doi: 10.1093/qjmed/hcu094. Epub 2014 Apr 28.</citation>
    <PMID>24778295</PMID>
  </reference>
  <reference>
    <citation>Spadaro G, Pecoraro A, De Renzo A, Della Pepa R, Genovese A. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol. 2016 May;166-167:103-4. doi: 10.1016/j.clim.2016.04.001. Epub 2016 Apr 7.</citation>
    <PMID>27063866</PMID>
  </reference>
  <reference>
    <citation>Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014 Jun;99(6):1101-6. doi: 10.3324/haematol.2013.101261. Epub 2014 Mar 28.</citation>
    <PMID>24682509</PMID>
  </reference>
  <reference>
    <citation>Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010 Apr;149(1):3-13. doi: 10.1111/j.1365-2141.2010.08076.x. Epub 2010 Feb 11. Review.</citation>
    <PMID>20151975</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rochester General Hospital</investigator_affiliation>
    <investigator_full_name>S. Shahzad Mustafa</investigator_full_name>
    <investigator_title>Physician, Associate Medical Director</investigator_title>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>Non Hodgkin's Lymphoma</keyword>
  <keyword>Subcutaneous Immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

